331 related articles for article (PubMed ID: 15550023)
1. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation.
Dhainaut JF; Yan SB; Joyce DE; Pettilä V; Basson B; Brandt JT; Sundin DP; Levi M
J Thromb Haemost; 2004 Nov; 2(11):1924-33. PubMed ID: 15550023
[TBL] [Abstract][Full Text] [Related]
2. The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.
Angus DC; Laterre PF; Helterbrand J; Ely EW; Ball DE; Garg R; Weissfeld LA; Bernard GR;
Crit Care Med; 2004 Nov; 32(11):2199-206. PubMed ID: 15640631
[TBL] [Abstract][Full Text] [Related]
3. Newly Proposed Sepsis-Induced Coagulopathy Precedes International Society on Thrombosis and Haemostasis Overt-Disseminated Intravascular Coagulation and Predicts High Mortality.
Iba T; Arakawa M; Di Nisio M; Gando S; Anan H; Sato K; Ueki Y; Levy JH; Thachil J
J Intensive Care Med; 2020 Jul; 35(7):643-649. PubMed ID: 29720054
[TBL] [Abstract][Full Text] [Related]
4. A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: comparison with a controlled clinical trial.
Wheeler A; Steingrub J; Schmidt GA; Sanchez P; Jacobi J; Linde-Zwirble W; Bates B; Qualy RL; Woodward B; Zeckel M
Crit Care Med; 2008 Jan; 36(1):14-23. PubMed ID: 18158435
[TBL] [Abstract][Full Text] [Related]
5. Safety of drotrecogin alfa (activated) in the treatment of patients with severe sepsis.
McCoy C
Expert Opin Drug Saf; 2004 Nov; 3(6):625-37. PubMed ID: 15500421
[TBL] [Abstract][Full Text] [Related]
6. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation.
Kienast J; Juers M; Wiedermann CJ; Hoffmann JN; Ostermann H; Strauss R; Keinecke HO; Warren BL; Opal SM;
J Thromb Haemost; 2006 Jan; 4(1):90-7. PubMed ID: 16409457
[TBL] [Abstract][Full Text] [Related]
7. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.
Payen D; Sablotzki A; Barie PS; Ramsay G; Lowry S; Williams M; Sarwat S; Northrup J; Toland P; McL Booth FV
Surgery; 2006 Nov; 140(5):726-39. PubMed ID: 17084715
[TBL] [Abstract][Full Text] [Related]
8. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.
Payen D; Sablotzki A; Barie PS; Ramsay G; Lowry S; Williams M; Sarwat S; Northrup J; Toland P; Booth FV
Surgery; 2007 Apr; 141(4):548-61. PubMed ID: 17431957
[TBL] [Abstract][Full Text] [Related]
9. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.
Abraham E; Laterre PF; Garg R; Levy H; Talwar D; Trzaskoma BL; François B; Guy JS; Brückmann M; Rea-Neto A; Rossaint R; Perrotin D; Sablotzki A; Arkins N; Utterback BG; Macias WL;
N Engl J Med; 2005 Sep; 353(13):1332-41. PubMed ID: 16192478
[TBL] [Abstract][Full Text] [Related]
10. Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial.
Laterre PF; Levy H; Clermont G; Ball DE; Garg R; Nelson DR; Dhainaut JF; Angus DC
Crit Care Med; 2004 Nov; 32(11):2207-18. PubMed ID: 15640632
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of modified non-overt DIC criteria on the prediction of poor outcome in patients with sepsis.
Oh D; Jang MJ; Lee SJ; Chong SY; Kang MS; Wada H
Thromb Res; 2010 Jul; 126(1):18-23. PubMed ID: 20079919
[TBL] [Abstract][Full Text] [Related]
12. Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis.
Laterre PF; Macias WL; Janes J; Williams MD; Nelson DR; Girbes AR; Dhainaut JF; Abraham E
Crit Care; 2008; 12(5):R117. PubMed ID: 18786266
[TBL] [Abstract][Full Text] [Related]
13. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis.
Ely EW; Laterre PF; Angus DC; Helterbrand JD; Levy H; Dhainaut JF; Vincent JL; Macias WL; Bernard GR;
Crit Care Med; 2003 Jan; 31(1):12-9. PubMed ID: 12544987
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Accuracy of the Different Scoring Systems for Assessing Coagulopathy in Sepsis: A Retrospective Study.
Chen Y; Chen W; Ba F; Zheng Y; Zhou Y; Shi W; Li J; Yang Z; Mao E; Chen E; Chen Y
Clin Appl Thromb Hemost; 2023; 29():10760296231207630. PubMed ID: 37920943
[TBL] [Abstract][Full Text] [Related]
15. Non-overt disseminated intravascular coagulation scoring for critically ill patients: the impact of antithrombin levels.
Egi M; Morimatsu H; Wiedermann CJ; Tani M; Kanazawa T; Suzuki S; Matsusaki T; Shimizu K; Toda Y; Iwasaki T; Morita K
Thromb Haemost; 2009 Apr; 101(4):696-705. PubMed ID: 19350114
[TBL] [Abstract][Full Text] [Related]
16. Comparison of a new criteria for sepsis-induced coagulopathy and International Society on Thrombosis and Haemostasis disseminated intravascular coagulation score in critically ill patients with sepsis 3.0: a retrospective study.
Ding R; Wang Z; Lin Y; Liu B; Zhang Z; Ma X
Blood Coagul Fibrinolysis; 2018 Sep; 29(6):551-558. PubMed ID: 30015646
[TBL] [Abstract][Full Text] [Related]
17. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial.
Nadel S; Goldstein B; Williams MD; Dalton H; Peters M; Macias WL; Abd-Allah SA; Levy H; Angle R; Wang D; Sundin DP; Giroir B;
Lancet; 2007 Mar; 369(9564):836-843. PubMed ID: 17350452
[TBL] [Abstract][Full Text] [Related]
18. Disseminated intravascular coagulation (DIC) diagnosed based on the Japanese Association for Acute Medicine criteria is a dependent continuum to overt DIC in patients with sepsis.
Gando S; Saitoh D; Ogura H; Mayumi T; Koseki K; Ikeda T; Ishikura H; Iba T; Ueyama M; Eguchi Y; Otomo Y; Okamoto K; Kushimoto S; Endo S; Shimazaki S;
Thromb Res; 2009 Mar; 123(5):715-8. PubMed ID: 18774163
[TBL] [Abstract][Full Text] [Related]
19. International integrated database for the evaluation of severe sepsis (INDEPTH): clinical evaluation committee report on the safety of drotrecogin alfa (activated) therapy.
Dhainaut JF;
Curr Med Res Opin; 2008 Apr; 24(4):1187-97. PubMed ID: 18348744
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of drotrecogin alfa (activated) for the therapy of surgical patients with severe sepsis.
Barie PS; Hydo LJ; Shou J; Eachempati SR
Surg Infect (Larchmt); 2006; 7 Suppl 2():S77-80. PubMed ID: 16895513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
